IL6 and glioma: Treatment with IL-6 pathway blockade via its receptor (IL-6R, tocilizumab) or binding soluble IL-6 (siltuximab) has been shown to inhibit glioma growth in vitro and reduce the expression of coinhibitory molecules such as PD-L1 on infiltrative myeloid cells [158,159].